Europe AI in Life Science Market (2026-2031)
The Europe AI in Life Science Market was valued at $2732.2 Million in 2026 and projected to reach to $8828.7 Million by 2031, representing a compound annual growth rate of 26.4%. Europe's AI in Life Science market is poised for transformative growth, supported by robust regulatory frameworks, substantial R&D investments, and a strong ecosystem of biotech and pharmaceutical companies.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Europe AI in Life Science Market Trends and Insights
- This represents a compound annual growth rate of 26.4%, reflecting Europe's strong commitment to digital transformation in healthcare and life sciences.
- Europe is leveraging advanced AI technologies across drug discovery, clinical diagnostics, and personalized medicine, driven by substantial R&D investments and regulatory support from the European Union. The European market benefits from a mature healthcare infrastructure, high adoption rates of digital health solutions, and a concentration of leading pharmaceutical and biotech companies.
- Europe's emphasis on data privacy through GDPR compliance and ethical AI frameworks positions the region as a leader in responsible AI implementation.
- Between 2026 and 2031, Europe is expected to capture significant market share through innovations in machine learning applications, real-world evidence generation, and AI-powered clinical trial optimization. Key growth catalysts for Europe include increased collaboration between academic institutions and industry, government funding initiatives, and the rising prevalence of chronic diseases requiring advanced diagnostic capabilities.
- Europe's competitive advantage lies in its skilled workforce, regulatory clarity, and commitment to sustainable healthcare innovation..
Key Market Statistics
- CAGR (2026-2031) 26.4% CAGR
- Market Size, 2026 ~USD 2732.2 Million
- Forecast, 2031 ~USD 8828.7 Million
- Geography Europe
Europe AI in Life Science Market Overview
Strong Market Valuation :
Europe's AI in Life Science market is valued at $2,732.2 million in 2026, with significant growth potential driven by regulatory support and healthcare digitalization initiatives across EU member states.
Exceptional Growth Trajectory :
With a CAGR of 26.4% through 2031, Europe's market is expanding at a rate nearly matching the global average of 26.3%, demonstrating the region's competitive positioning in AI-driven life sciences innovation.
Leading European Markets :
Germany ($3,566.4M), UK ($3,135.3M), and France ($2,547.8M) are the dominant markets in Europe, collectively representing over 60% of the region's AI in Life Science sector value.
Projected Market Expansion :
Europe's market is forecast to reach $8,828.7 million by 2031, representing a 223% increase from 2026 levels, reflecting accelerating adoption of AI in drug discovery, diagnostics, and personalized medicine.
Europe AI in Life Science Market Dynamics
- The region's commitment to digital health initiatives and precision medicine is driving widespread adoption of AI technologies across drug discovery, clinical diagnostics, and patient management systems.
- Key European markets including Germany, the UK, and France are leading innovation efforts, while emerging markets within the region contribute to overall expansion. The forecast period through 2031 will be characterized by increased collaboration between academic institutions, healthcare providers, and technology companies.
- Europe's emphasis on data privacy through GDPR compliance and ethical AI development creates competitive advantages in global markets.
- Investment in AI infrastructure, talent development, and cross-border partnerships will further accelerate market penetration, positioning Europe as a critical hub for AI-enabled life sciences innovation..
Related Ecosystem
Healthcare It
- Computed Tomography (CT)
- Machine Learning
- Magnetic Resonance Imaging (MRI)
- Natural Language Processing (NLP)
- Predictive Analytics
- CERNER CORPORATION
- PHILIPS HEALTHCARE
- Oracle Corporation
- GE HealthCare Technologies Inc.
- Siemens healthineers
Key Takeaways
- Europe's AI in Life Science market will grow from $2,732.2M (2026) to $8,828.7M (2031) at a 26.4% CAGR, outpacing global growth trends.
- Europe leads in ethical AI implementation and GDPR-compliant solutions, establishing regulatory best practices for the global life sciences industry.
- Strong pharmaceutical and biotech ecosystems across Europe drive adoption of AI in drug discovery, clinical trials, and precision medicine applications.
- Europe's mature healthcare infrastructure and government funding initiatives position the region as a hub for AI-driven healthcare innovation through 2031.
AI in Life Science Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2026 |
| Fastest Growing Segment | NATURAL LANGUAGE PROCESSING (Tool) |
| Forecast Period | 2026–2031 |
| Growth Rate | CAGR of 26.3% from 2026 to 2031 |
| Largest Segment | CLINICAL APPLICATIONS (Application) |
| Market Size Base Year (Billions) | ~USD 21.58 (2026) |
| Revenue Forecast (Billions) | ~USD 69.34 (2031) |
| Segments Covered | Tool, Type, Application, Component, Deployment, End User, Offering, Deployment Mode |
Europe AI in Life Science Market Report Segmentation
8 segment dimensions are covered across the global market.
By Tool
- Computer Vision
- Context-Aware Processing And Computing
- Image Analysis (Including Optical Character Recognition)
- Machine Learning
- Natural Language Processing
By Type
- Clinical Trials
- Convolutional Neural Networks
- Data Analytics & Reporting
- Deep Learning
- Drug Discovery
- Generative Adversarial Networks
- Graph Neural Networks
- Manufacturing & Quality Assurance
- Medical Imaging & Diagnostics
- Other Clinical Applications
- Other Machine Learning Technologies
- Precision Medicine
- R&D Support
- Recurrent Neural Networks
- Regulatory Affairs
- Reinforcement Learning
- Supervised Learning
- Unsupervised Learning
By Application
- Clinical Applications
- Non-Clinical Applications
By Component
- Service
- Services
- Software
By Deployment
- Cloud-Based Solutions
- Hybrid Solutions
- On-Premise Solutions
By End User
- Academic & Government Laboratories
- Biotechnology Companies
- Cro & Cdmo
- Diagnostic Companies
- Other End Users
- Pharmaceutical Companies
By Offering
- AI Technology
- End-To-End Solutions
- Niche/Point Solutions
- Services
By Deployment Mode
- Cloud-Based Solutions
- Hybrid Solutions
- On-Premise Solutions
EUROPE: AI IN LIFE SCIENCE MARKET, BY END USER, 2024–2031
| Segment | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| ACADEMIC & GOVERNMENT LABORATORIES | 221.8 | 274.2 | 345.9 | 438.7 | 549.9 | 696 | 875.2 | 1088.2 | 25.8 |
| BIOTECHNOLOGY COMPANIES | 704.8 | 877.5 | 1114.6 | 1423.5 | 1797.1 | 2290.2 | 2900.2 | 3631.2 | 26.6 |
| CRO & CDMO | 532.6 | 659.3 | 832.7 | 1057.6 | 1327.6 | 1682.3 | 2118.3 | 2637.2 | 25.9 |
| DIAGNOSTIC COMPANIES | 289.7 | 359.9 | 456.2 | 581.5 | 732.7 | 931.8 | 1177.7 | 1471.6 | 26.4 |
| OTHER END USERS | 144.7 | 178.4 | 224.3 | 283.5 | 354.1 | 446.5 | 559.2 | 692.5 | 25.3 |
| PHARMACEUTICAL COMPANIES | 1264.7 | 1572.3 | 1994.2 | 2543.4 | 3206.2 | 4080.1 | 5159.3 | 6450.5 | 26.5 |
| TOTAL | 3158.2 | 3921.7 | 4967.9 | 6328.2 | 7967.6 | 10126.8 | 12789.9 | 15971.2 | 26.3 |
REST OF EUROPE: AI IN LIFE SCIENCE MARKET, BY END USER, 2024–2031
| Segment | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| ACADEMIC & GOVERNMENT LABORATORIES | 44.6 | 55 | 69.2 | 87.6 | 109.6 | 138.4 | 173.7 | 215.5 | 25.5 |
| BIOTECHNOLOGY COMPANIES | 153.8 | 191 | 242.1 | 308.4 | 388.5 | 493.8 | 623.8 | 779.1 | 26.3 |
| CRO & CDMO | 104.7 | 129.4 | 163 | 206.6 | 258.8 | 327.2 | 411 | 510.5 | 25.6 |
| DIAGNOSTIC COMPANIES | 54.9 | 68.1 | 86.1 | 109.5 | 137.7 | 174.7 | 220.2 | 274.5 | 26.1 |
| OTHER END USERS | 36.6 | 45.1 | 56.6 | 71.5 | 89.2 | 112.4 | 140.7 | 174.1 | 25.2 |
| PHARMACEUTICAL COMPANIES | 255.1 | 316.5 | 400.5 | 509.7 | 641 | 813.9 | 1026.9 | 1280.8 | 26.2 |
| TOTAL | 649.7 | 805 | 1017.6 | 1293.4 | 1624.8 | 2060.4 | 2596.3 | 3234.6 | 26 |
Target Audience
- Pharmaceutical & Biotech Companies : European and global pharma firms need market-specific insights to optimize AI investments in drug discovery and development, identify partnership opportunities with European biotech innovators, and navigate country-specific regulatory pathways.
- Healthcare IT & AI Solution Providers : Software vendors and AI platform companies require detailed European market segmentation to prioritize market entry, tailor solutions to regional healthcare systems, and identify high-growth country opportunities for expansion.
- Healthcare Providers & Hospital Networks : European hospitals and healthcare systems need competitive intelligence on AI diagnostic and clinical tools available in their markets, benchmarking data against peer institutions, and ROI projections for AI implementation decisions.
- Investment & Private Equity Firms : Investors targeting European life sciences need market sizing, growth forecasts, and country-level opportunity analysis to identify acquisition targets, evaluate portfolio company positioning, and assess market timing for exits.
- Government & Healthcare Policy Bodies : European health ministries and regulatory agencies require market data to inform digital health strategies, assess AI adoption rates, benchmark against peer nations, and develop evidence-based healthcare innovation policies.
Key Companies in the Europe AI in Life Science Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| NVIDIA CORPORATION | United States | Public Company | Data Center AI & Accelerated Computing (Compute & Networking),Gaming GPUs (GeForce),Professional Visualization (RTX/Quadro), |
| ILLUMINA, INC. | United States | Public Company | Sequencing instruments,Sequencing consumables (reagents, flow cells, library prep, WGS and targeted kits),Array-based instruments and consumables, |
| TEMPUS AI, INC. | United States | Public Company | Oncology NGS diagnostics (xT, xR, large-panel solid and hematologic assays),Other clinical diagnostics (PCR, pathology, germline, pharmacogenomics nP),Life sciences data, AI platforms, and software (Lens, Insights, Next, Algos, Organoids, Trials), |
| RECURSION | United States | Public Company | Platform and collaboration revenue,Internal pipeline and other revenue, |
| DASSAULT SYSTèMES SE | France | Public Company | 3D Modeling (CATIA, SOLIDWORKS, GEOVIA, BIOVIA),PLM & Collaboration (ENOVIA, CENTRIC PLM, 3DEXCITE, 3DEXPERIENCE collaboration),Simulation & Manufacturing (SIMULIA, DELMIA, 3DVIA), |
| SCHRÖDINGER, INC. | United States | Public Company | Software,Drug Discovery – Collaborations and Milestones,Drug Discovery – Internal Programs and Other, |
| MICROSOFT CORPORATION | United States | Public Company | Productivity and Business Processes,Intelligent Cloud,Personal Computing, |
| BENEVOLENTAI LIMITED | United Kingdom | Private Company | AI R&D decision-support platform (licenses and subscriptions),Collaborative discovery projects and services,Data and ontology integration / customization, |
NVIDIA CORPORATION
NVIDIA Corporation is a U.S. public company founded in 1993 that employs 42,000 people. The company designs and manufactures graphics processing units and system-on-chip units for gaming, professional visualization, data centers, and artificial intelligence applications.
ILLUMINA, INC.
Illumina, Inc. is a U.S. public company founded in 1998 with 8,625 employees. The company develops and manufactures sequencing and array-based solutions for genetic analysis and molecular diagnostics.
TEMPUS AI, INC.
Tempus AI, Inc. is a U.S. public company founded in 2015 with 3,800 employees. The company applies artificial intelligence and machine learning to healthcare data to improve clinical decision-making and patient outcomes.
RECURSION
Recursion is a U.S. public company founded in 2013 with 600 employees. The company uses artificial intelligence and high-throughput biology to discover and develop novel therapeutics.
DASSAULT SYSTèMES SE
Dassault Systèmes SE is a French public company founded in 1981 with 25,000 employees. The company develops and markets 3D design, digital mock-up, and product lifecycle management software solutions.
SCHRÖDINGER, INC.
Schrödinger, Inc. is a U.S. public company founded in 1990 with 850 employees. The company provides computational chemistry and molecular simulation software platforms for drug discovery and materials science.
MICROSOFT CORPORATION
Microsoft Corporation is a U.S. public company founded in 1975 with 228,000 employees. The company develops, manufactures, and sells computer software, consumer electronics, personal computers, and cloud computing services.
BENEVOLENTAI LIMITED
BenevolentAI Limited is a United Kingdom private company founded in 2013 with 173 employees. The company uses artificial intelligence to accelerate drug discovery and development for various therapeutic areas.
Countries within Europe - compare and drill down
| Country | 2025 size (native) |
|---|---|
| Germany | USD 3566.4 Million |
| France | USD 2547.8 Million |
| UK | USD 3135.3 Million |
| Italy | USD 1943.4 Million |
| Spain | USD 1543.8 Million |
| Rest Of Europe | USD 3234.6 Million |
Country market size visualization
Reasons to Buy this Report
- Country-Level Market Intelligence : Access detailed market sizing and growth projections for Germany, UK, France, Italy, Spain, and Rest of Europe, enabling precise market entry and expansion strategies tailored to each country's regulatory and competitive landscape.
- Competitive Positioning Analysis : Understand how Europe's 26.4% CAGR compares to global trends and identify which European markets are outperforming, helping you allocate resources to highest-opportunity regions.
- Regulatory & Compliance Insights : Navigate Europe's complex regulatory environment including GDPR, CE marking, and EMA requirements with market context specific to each country's healthcare AI adoption patterns and compliance frameworks.
- Investment & Partnership Opportunities : Identify emerging opportunities across Europe's fragmented but high-growth markets, from established leaders like Germany to high-growth emerging markets, with data-driven insights for M&A and partnership decisions.
- Forecast-Driven Strategic Planning : Leverage 2031 projections showing $8.8B market size to develop long-term product roadmaps, market expansion timelines, and resource allocation strategies aligned with Europe's accelerating AI adoption trajectory.
Frequently asked questions
What is the projected market size for AI in Life Science in Europe by 2031?
Europe's AI in Life Science market is projected to reach $8,828.7 million by 2031, growing from $2,732.2 million in 2026.
What is the CAGR for AI in Life Science in Europe?
Europe's AI in Life Science market is expected to grow at a compound annual growth rate of 26.4% between 2026 and 2031.
What are the primary drivers of AI adoption in Europe's life sciences sector?
Key drivers include strong R&D investments, EU regulatory support, GDPR-compliant data frameworks, collaboration between academia and industry, and the need for advanced diagnostic solutions.
How does Europe's AI in Life Science market compare to global trends?
Europe's 26.4% CAGR aligns closely with the global 26.3% CAGR, demonstrating that Europe is a major contributor to worldwide AI in life sciences growth.
What regulatory advantages does Europe offer for AI in life sciences?
Europe's GDPR compliance framework, ethical AI guidelines, and transparent regulatory environment provide competitive advantages for responsible AI implementation in healthcare and life sciences.
RESEARCH METHODOLOGY
The study involved five major activities to estimate the current size of the AI in life science market. Exhaustive secondary research was conducted to collect information on the market and its subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the total market size. Thereafter, market breakdown and data triangulation procedures were used to estimate the market size of the segments and subsegments.
Secondary Research
In the secondary research process, various secondary sources, including annual reports, press releases and investor presentations from companies, white papers, certified publications, articles by recognized authors, gold- and silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva), were consulted to identify and collect information for the study of the AI in the life science market. These sources were also used to obtain important information about the top players, market classification and segmentation by industry trends down to the bottom-most level, geographic markets, and key developments related to the market. A database of key industry leaders was also prepared using secondary research.
Primary Research
Extensive primary research was conducted after obtaining basic information of the global AI in life science market through secondary research. Several primary interviews were conducted with market experts from both the demand side (hospital directors, hospital vice presidents, department heads, and critical care specialists) and the supply side (such as C- and D-level executives, technology experts, product managers, marketing and sales managers, among others) across five major regions, including North America, Europe, the Asia-Pacific, Latin America, the Middle East, and Africa. This primary data was collected through questionnaires, emails, online surveys, personal interviews, and telephone interviews.
The following is a breakdown of the primary respondents:
BREAKDOWN OF PRIMARY PARTICIPANTS:
Note 1: Others include sales managers, marketing managers, and product managers.
Note 2: Tiers of companies are defined on the basis of their total revenues in 2025. Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = <USD 500 million.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the total size of the AI in life science market. These methods were also used extensively to estimate the size of various subsegments in the market.
AI in Life Science Market : Top-Down and Bottom-Up Approach
Data Triangulation
After determining the overall market size using market size estimation processes, the market was segmented into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for each market segment and subsegment, data triangulation and market breakdown procedures were employed wherever applicable. The data was triangulated by analyzing various factors and trends from both the demand and supply sides in the AI in life science market.
Market Definition
AI in life sciences refers to the application of artificial intelligence technologies to analyze complex biological, clinical, and healthcare data to improve research, development, and patient outcomes. It uses advanced algorithms and computational models to support areas such as drug discovery, disease diagnosis, clinical trials, and precision medicine, enabling faster insights and more efficient decision-making across the life sciences ecosystem.
Key Stakeholders
- Pharmaceutical & Biotechnology Companies
- Contract Research Organizations (CROs) & Clinical Trial Partners
- Healthcare Providers (Hospitals, Clinics, Telehealth Providers)
- Digital Health & AI Solution Providers
- Cloud & Data Infrastructure Providers
- Data Analytics & Software Platform Providers
- Payers & Insurance Companies
- Regulatory & Compliance Bodies (e.g., FDA, EMA)
- Academic & Research Institutions
- Patients & End Users
- Technology Integrators & Consulting Firms
Report Objectives
- To define, describe, and forecast the global AI in life science market based on type, therapeutic area, application, end user, and region
- To provide detailed information regarding the major factors (such as drivers, restraints, opportunities, and challenges) influencing market growth
- To strategically analyze micro-markets with respect to individual growth trends, prospects, and contributions to the overall AI in life science market
- To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To strategically analyze the market structure profile of the key players of the AI in life science market and comprehensively analyze their core competencies
- To forecast the size of the market segments with respect to five regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa
- To analyze competitive developments such as product launches and enhancements, investments, partnerships, collaborations, acquisitions, expansions, product approval, and alliances in the AI in life science market during the forecast period
Available customizations:
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:
Product Analysis
- Product matrix, which gives a detailed comparison of the product portfolios of each company.
Regional Analysis
- Further breakdown of the Latin America, Europe, and Middle East & Africa AI in life science market into specific countries
Get the Full AI in Life Science Market Report
Full forecast, segment splits, and company analysis for all AI in Life Science Market.
- US AI in Life Science Market
- Canada AI in Life Science Market
- Germany AI in Life Science Market
- France AI in Life Science Market
- UK AI in Life Science Market
- Italy AI in Life Science Market
- Spain AI in Life Science Market
- China AI in Life Science Market
- Japan AI in Life Science Market
- India AI in Life Science Market
- Australia AI in Life Science Market
- South Korea AI in Life Science Market
- Brazil AI in Life Science Market
- Mexico AI in Life Science Market
- Saudi Arabia AI in Life Science Market
- UAE AI in Life Science Market
- South Africa AI in Life Science Market
- Rest Of Europe AI in Life Science Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report